**Letter**

**Live virus neutralization testing in convalescent patients and subjects vaccinated against 19A, 20B, 20I/501Y.V1 and 20H/501Y.V2 isolates of SARS-CoV-2**

Carla Saade, Claudia Gonzalez, Antonin Bal, Martine Valette, Kahina Saker, Bruno Lina, Laurence Josset, Guillaume Thiery, Elisabeth Botelho-Nevers, Stéphane Paul, Paul Verhoeven, Thomas Bourlet, Sylvie Pillet, Florence Morfin, Sophie Trouillet-Assant and Bruno Pozzetto on behalf of COVID-SER study group

Abstract

SARS-CoV-2 mutations appeared recently and can lead to conformational changes in the spike protein and probably induce modifications in antigenicity. We assessed the neutralizing capacity of antibodies to prevent cell infection, using a live virus neutralization test with different strains [19A (initial one), 20B (B.1.1.241 lineage), 20I/501Y.V1 (B.1.1.7 lineage), and 20H/501Y.V2 (B.1.351 lineage)] in serum samples collected from different populations: two-dose vaccinated COVID-19 naïve healthcare workers (HCWs; Pfizer-BioNTech BNT161b2), 6-months post mild COVID-19 HCWs, and critical COVID-19 patients. No significant difference was observed between the 20B and 19A isolates for HCWs with mild COVID-19 and critical patients. However, a significant decrease in neutralization ability was found for 20H/501Y.V2 in comparison with 19A isolate for critical patients and HCWs 6-months post infection. Concerning 20H/501Y.V2, all populations had a significant reduction in neutralizing antibody titers in comparison with the 19A isolate. Interestingly, a significant difference in neutralization capacity was observed for vaccinated HCWs between the two variants but not in the convalescent groups.

**ARTICLE HISTORY** Received 29 April 2021; Revised 14 June 2021; Accepted 16 June 2021

**KEYWORDS** SARS-CoV-2; humoral response; variant of concern; live virus neutralization test; 20B; 20I/501Y.V1; 20H/501Y.V2

Several SARS-CoV-2 variants of concern (VOC) with mutations impacting notably the spike (S) protein have been detected recently [1]. These mutations can lead to conformational changes and probably induce modifications in antigenicity. Serological studies based on SARS-CoV-2 pseudotyped or chimeric viruses have been performed to measure the neutralization activity of serum specimens of convalescent patients or subjects immunized by SARS-CoV-2 vaccines. Although these tests are easier to conduct, their ability to predict neutralizing activity against authentic clinical viral isolates needs to be evaluated [2].

In this study, we compared the ability of neutralizing antibodies (NAb) directed against SARS-CoV-2 to prevent cell infection in different populations, using a live Virus Neutralization Test (VNT) against SARS-CoV-2 isolates belonging to various clades: 19A, 20B (B.1.1.241 lineage), 20I/501Y.V1 (B.1.1.7 lineage) and 20H/501Y.V2 (B.1.351 lineage). Each SARS-CoV-2 isolate used in this study was sequenced to confirm the characteristic mutations in antigenicity. We assessed the neutralizing capacity of antibodies to prevent cell infection, using a live virus neutralization test with different strains [19A (initial one), 20B (B.1.1.241 lineage), 20I/501Y.V1 (B.1.1.7 lineage), and 20H/501Y.V2 (B.1.351 lineage)] in serum samples collected from different populations: two-dose vaccinated COVID-19 naïve healthcare workers (HCWs; Pfizer-BioNTech BNT161b2), 6-months post mild COVID-19 HCWs, and critical COVID-19 patients. No significant difference was observed between the 20B and 19A isolates for HCWs with mild COVID-19 and critical patients. However, a significant decrease in neutralization ability was found for 20H/501Y.V2 in comparison with 19A isolate for critical patients and HCWs 6-months post infection. Concerning 20H/501Y.V2, all populations had a significant reduction in neutralizing antibody titers in comparison with the 19A isolate. Interestingly, a significant difference in neutralization capacity was observed for vaccinated HCWs between the two variants but not in the convalescent groups.

**CONTACT** Bruno Pozzetto brunopozzetto@univ-st-etienne.fr CIRI, équipe GIMAP, Université de Lyon, Université de Saint-Etienne, INSERM U1111, CNRS UMR3308, ENS de Lyon, UCL1, 42023 Saint-Etienne, France

© 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group, on behalf of Shanghai Shangyixun Cultural Communication Co., Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Figure 1. Neutralization of living isolates of SARS-CoV-2 by convalescent sera from critical or mild patients with COVID-19 and by vaccine-elicited sera from subjects having received two doses of the BNT162b2 vaccine. Each serum was tested in duplicate and the mean NAb was used for the analysis. Titres were transformed into log2 values for the calculation of mean NAb titres (a value of 0.5 was attributed by convention to negative samples). Dotted lines represent the detection threshold of 50% plaque reduction neutralization test (PRNT50) ≥20 for neutralizing antibody (NAb) titres; full lines represent median NAb titres and dashedotted lines represent the 25% and 75% quartiles. (A) Violin plots presenting the neutralization of 2 SARS-CoV-2 isolates belonging to the 19A and 20B clades by serum specimens obtained from critical patients (n = 27), 6-month post mild COVID-19 healthcare workers (HCWs) (n = 19) and vaccinated subjects (n = 15); the Wilcoxon matched-pair signed rank test was used for comparisons. (B) Violin plots presenting the neutralization of a SARS-CoV-2 isolate belonging to the 19A clade by serum specimens obtained from vaccinated subjects (n = 30), 6-month post mild COVID-19 HCWs (n = 29) and critical patients (n = 25); the Kruskal-Wallis test followed by Dunn’s multiple comparison test was used for comparisons. (C) Violin plots presenting the neutralization of 3 SARS-CoV-2 isolates belonging to the 19A, 20I/S01Y.V1 and 20H/S01Y.V2 clades by the same serum specimens than in (B); the Friedman test followed by the Dunn’s multiple comparison test was used for comparisons. For each VOC, the fold reduction in NAb titres compared to 19A is shown under the statics bar.

*: p-value < 0.05; **: p-value < 0.01; ***: p-value < 0.001; ****: p-value < 0.0001; ns: non-significant.
exhibiting significant NAb against 19A (50% plaque reduction neutralization test (PRNT₅₀) ranging from 20 to 240) 6 months after mild COVID-19 (n = 29; group 2) [5], and critical COVID-19 patients sampled within one month after symptom onset (median [interquartile range, IQR]: 28 [22.5–33.5] days; n = 25; group 3). All COVID-19 patients from groups 2 and 3 had been infected during the first wave of COVID-19 that occurred in France in March–April of 2020. Written informed consent was obtained from all HCWs; ethics approval was obtained from the national review board for biomedical research in April 2020 (Comité de Protection des Personnes Sud Méditerranée 1, Marseille, France; ID RCB 2020-A00932-37), and the study was registered on ClinicalTrials.gov (NCT04341142). Concerning critical patients, this study was approved by the ethics committee of the university hospital of Saint-Etienne (reference number IRBN512020/CHUSTE).

No significant difference in median NAb titres was observed on a subset of serum specimens taken from the three populations between the 19A isolate taken as reference and the 20B isolate that circulated during the second pandemic wave at the end of 2020 in Europe (Figure 1(A)). Even if this result was expected, it had not been reported before; it indicates that the S477N mutation has no impact on the ability of NAb to confer protection.

As previously reported between mild and severe patients [3], the three populations exhibited significantly different median levels of NAb for 19A isolate (Figure 1(B)); the same picture was observed for the two VOC (data not shown).

By comparison to the 19A isolate, the median [IQR] fold reduction in NAb titres was 1.5 [1.2–1.7] and 3.5 [2.7–4.3] in group 1, 1.6 [1.3–1.8] and 1.9 [1.5–2.3] in group 2, and 2.3 [1.8–2.8] and 2.2 [1.5–2.8] in group 3, for the 20I/501Y.V1 and 20H/501Y.V2 VOC respectively (Figure 1(C)). Interestingly, the difference in median NAb titres was highly significant between the two variants (p < 0.001) for vaccinated subjects (group 1) whereas it was not significant for the two other groups corresponding to naturally infected patients (Figure 1(C)).

As a whole, critical patients exhibited a strong neutralizing response against all the tested strains; despite a slight reduction in NAb titres for both variants by comparison to the wild-type strain, no neutralization escape occurred against the two VOC due to the high titres of NAb. This population of subjects has not been tested in previous studies involving the neutralization escape to VOC strains; additional data are needed to confirm this reassuring observation.

The 6-month neutralizing response of HCWs with mild COVID-19 was slightly reduced towards both variants by comparison to the wild type strain. By contrast to that reported herein, a study performed with pseudotype viruses on the same category of patients (6-month mild COVID-19 HCWs) found that the neutralizing response was much lower against the 20H/501Y.V2 variant than against the 20I/501Y.V1 one [6], which would suggest an increased risk of neutralization escape with the former strain.

Another striking finding of the present study is the reduced neutralizing response observed towards the 20H/501Y.V2 variant in fully immunized subjects with the BNT162b2 vaccine by comparison to the wild type and 20I/501Y.V1 variant. These results are in accordance with that observed for the same vaccine in numerous studies using pseudotype viruses [6–9] or authentic variant strains [10–13]. The neutralization escape of the 20H/501Y.V2 variant in subjects having received either the BNT162b2 vaccine [11–14] or the Oxford-AstraZeneca AZD1222 vaccine [14] was shown to be mainly mediated by the synergistic effect of mutations K417N, E484K and N501Y in the receptor binding domain. This effect was in part corrected by a hyper-immunization like that observed in naturally infected people whose immunity was boosted by an additional dose of vaccine [15].

Although the present study was performed using a live VNT, it focused only on the humoral response and other experiments are needed to assess the overall immune process including T-cell immune response. Another limitation of the study regards the huge differences between the three tested populations in terms of time post-infection or immunization, which restrains the interpretation of the differences in results between the three groups.

In conclusion, the relative good conservation of the neutralizing activity of sera from the three populations tested in this study against the two variants 20I/501Y.V1 and 20H/501Y.V2 is encouraging towards a putative re-infection by these strains. Long-term monitoring of the NAb response together with that of the specific cellular response will be needed to confirm these favourable findings.

Acknowledgements

We are indebted to all the personnel of the occupational health and medicine department of Hospices Civils de Lyon who contributed to the collection of samples, especially Virginie Pitiot, Fanny Joubert and PMO team. Human biological samples and associated data were obtained from NeuroBioTec (CRB HCL, Lyon France, Biobank BB-0033-00046). We thank Karima Brahami and all members of the clinical research and innovation department for their reactivity (DRS, Hospices Civils de Lyon). All members of Saint-Etienne Hospital who contributed to the collection of samples are acknowledged. COVID-SER study group: Alfaiate Dulce, d’Aubarede Constance, Escuret Vanessa, Fassier Jean-Baptiste, Gaymard Alexandre, Grégory Destras, Guibert Nicolas, Lozano Hélène, Massardier-Pilonchery Amélie, Pitiot Virginie.
Disclosure statement

Antonin Bal received a grant from bioMerieux and served as consultant for bioMerieux for work and research not related to this manuscript. Sophie Trouillet-Assant received a research grant from bioMerieux concerning previous works not related to this manuscript. The other authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript.

Funding

This research is being supported by Hospices Civils de Lyon, Fondation des Hospices Civils de Lyon, and a grant from the GIMAP team of the University Hospital of Saint-Etienne (Grant reference: the ASSE Coeur-vert association).

Data availability statement

GISAID accession numbers: EPI_ISL_1707038; EPI_ISL_1707039; EPI_ISL_1707040; EPI_ISL_768828.

ORCID

Carla Saade http://orcid.org/0000-0001-5964-0588
Claudia Gonzalez http://orcid.org/0000-0002-0855-939X
Antonin Bal http://orcid.org/0000-0002-0261-2495
Kahina Saker http://orcid.org/0000-0001-8825-5400
Bruno Lina http://orcid.org/0000-0002-8599-2123
Laurence Josset http://orcid.org/0000-0002-7158-1186
Mary-Anne Trabaud http://orcid.org/0000-0001-8614-1071
Guillaume Thiery http://orcid.org/0000-0002-8786-9061
Elisabeth Botelho-Nevers http://orcid.org/0000-0003-2773-7750
Stéphane Paul http://orcid.org/0000-0002-8830-4273
Paul Verhoeven http://orcid.org/0000-0003-4352-1263
Thomas Bourlet http://orcid.org/0000-0002-9226-1149
Sylvie Pillet http://orcid.org/0000-0002-0882-3162
Florence Morfin http://orcid.org/0000-0002-1962-808X
Sophie Trouillet-Assant http://orcid.org/0000-0001-6439-4705
Bruno Pozzetto http://orcid.org/0000-0002-2603-8467

References

[1] Plante JA, Mitchell BM, Plante KS, et al. The variant gambit: COVID-19’s next move. Cell Host Microbe. 2021;29:508–515.
[2] Schmidt F, Weisblum Y, Muecksch F, et al. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. J Exp Med. 2020;217:e20201181.
[3] Legros V, Denollet S, Vogrinc M, et al. A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity. Cell Mol Immunol. 2021;18:318–327.
[4] Bal A, Pozzetto B, Trabaud MA, et al. Evaluation of high-throughput SARS-CoV-2 serological assays in a longitudinal cohort of patients with mild COVID-19: clinical sensitivity, specificity and association with virus neutralization test. Clin Chem. 2021;67:742–752.
[5] Bal A, Trabaud MA, Fassier JB, et al. Six-month antibody response to SARS-CoV-2 in healthcare workers assessed by virus neutralization and commercial assays. Clin Microbiol Infect. 2021;27:933–935.
[6] Kuzmina A, Khalaila Y, Voloshin O, et al. SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera. Cell Host Microbe. 2021;29:522–528.e2.
[7] Garcia-Beltran WF, Lam EC, St Denis K, et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell. 2021;184:2372–2383.e9.
[8] Xie X, Liu Y, Liu J, et al. Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. Nat Med. 2021;27:620–621.
[9] Abdool Karim SS, de Oliveira T. New SARS-CoV-2 variants – clinical, public health, and vaccine implications. N Engl J Med. 2021;384:1866–1868.
[10] Planas D, Bruel T, Grzelak L, et al. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. Nat Med. 2021;27:917–924.
[11] Wang P, Nair MS, Liu L, et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature. 2021;59:130–135.
[12] Liu Y, Liu J, Xia H, et al. Neutralizing activity of BNT162b2-elicited serum. N Engl J Med. 2021;384:1466–1468.
[13] Chen RE, Zhang X, Case JB, et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat Med. 2021;27:717–726.
[14] Zhou D, Dejnirattisai W, Supasa P, et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell. 2021;184:2348–2361.e6.
[15] Lustig Y, Nemet I, Kliker L, et al. Neutralizing response against variants after SARS-CoV-2 infection and one dose of BNT162b2. N Engl J Med. 2021 Apr 7; NEJMc2104036. doi: 10.1056/NEJMc2104036. Épub ahead of print.